Infection with the SARS-CoV-2 Omicron variant is associated with less severe disease compared with the Delta variant.1- 3 Two main Omicron sublineages—BA.1 and BA.2—have variable geographic distribution. In Qatar, BA.1 was initially predominant but was quickly replaced by BA.2 as the predominant sublineage. This study sought to determine and compare the severity of SARS-CoV-2 infection among persons infected with these sublineages.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: June 18, 2022.
Published Online: August 22, 2022. doi:10.1001/jamainternmed.2022.3351
Corresponding Author: Adeel A. Butt, MBBS, MS, Hamad Medical Corporation, PO Box 3050, Doha, Qatar (firstname.lastname@example.org).
Author Contributions: Drs Butt and Abu-Raddad had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Butt, Al Khal, Abou-Samra, Abu-Raddad.
Acquisition, analysis, or interpretation of data: Butt, Dargham, Coyle, Yassine, Abu-Raddad.
Drafting of the manuscript: Butt, Abu-Raddad.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Butt, Dargham, Abu-Raddad.
Administrative, technical, or material support: Butt, Al Khal, Abou-Samra, Abu-Raddad.
Other−data related to identifying variants circulation: Yassine.
Conflict of Interest Disclosures: Dr Butt reported grants from Gilead Sciences to the institution, outside the submitted work. No other disclosures were reported.
Disclaimer: Data used in this study were collected as a part of the Qatar national COVID-19 response and was overseen by the Ministry of Public Health and Hamad Medical Corporation. Neither had a role in the analysis or interpretation of the data, preparation, review, or approval of the manuscript, nor the decision to submit the manuscript for publication. The views expressed in this article are those of the authors and do not necessarily represent official government views or policy of the State of Qatar or the Hamad Medical Corporation.
Additional Contributions: The authors are grateful for the leadership and assistance provided by the Ministry of Public Health in Qatar, the System-Wide Incident Command and Control Center, and the Business Intelligence Unit at Hamad Medical Corporation. We are also grateful for the dedicated frontline health care workers who have selflessly served and provided care and comfort to all patients in Qatar. We acknowledge the data, viral genome sequencing, and logistical efforts of the National Study Group for COVID-19 Epidemiology including Hebah A. Al Khatib, PhD, Gheyath K. Nasrallah, PhD, Houssein H. Ayoub, PhD (Qatar University); Srusvin Loca, BCA, Anvar H. Kaleeckal, MSc, Ali Nizar Latif, MD, Riyazuddin M. Shaik, MSc (Hamad Medical Corporation); Patrick Tang, MD, PhD (Sidra Medicine); and Roberto Bertollini, MD, MPH (Ministry of Public Health, Doha, Qatar). We also acknowledge the statistical and data management support of Hiam Chemaitelly, PhD, and administrative support of Adona Canlas, BSc (Weill Cornell Medicine–Qatar, Cornell University). We are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine–Qatar. We are also grateful for the Qatar Genome Program for supporting the viral genome sequencing. None of the additional contributors received any compensation for their contributions.
You currently have no searches saved.
You currently have no courses saved.